Annual SGA
$7.12 M
-$2.74 M-27.77%
December 31, 2023
Summary
- As of February 24, 2025, TOVX annual SGA is $7.12 million, with the most recent change of -$2.74 million (-27.77%) on December 31, 2023.
- During the last 3 years, TOVX annual SGA has risen by +$2.09 million (+41.58%).
- TOVX annual SGA is now -29.80% below its all-time high of $10.14 million, reached on December 1, 2016.
Performance
TOVX SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly SGA
$2.30 M
+$835.00 K+56.92%
September 1, 2024
Summary
- As of February 24, 2025, TOVX quarterly SGA is $2.30 million, with the most recent change of +$835.00 thousand (+56.92%) on September 1, 2024.
- Over the past year, TOVX quarterly SGA has stayed the same.
- TOVX quarterly SGA is now -49.26% below its all-time high of $4.54 million, reached on March 1, 2001.
Performance
TOVX Quarterly SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM SGA
-$1.28 B
-$26.69 M-2.13%
September 1, 2024
Summary
- As of February 24, 2025, TOVX TTM SGA is -$1.28 billion, with the most recent change of -$26.69 million (-2.13%) on September 1, 2024.
- Over the past year, TOVX TTM SGA has dropped by -$1.28 billion (-16636.64%).
- TOVX TTM SGA is now -6229778.05% below its all-time high of -$20.50 thousand.
Performance
TOVX TTM SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Selling, General & Administrative Expenses Formula
SGA = Total Operating Expenses - Cost of Goods Sold - Research & Development
TOVX Selling, General & Administrative Expenses Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
---|---|---|---|
1 y1 year | -27.8% | 0.0% | -10000.0% |
3 y3 years | +41.6% | 0.0% | -10000.0% |
5 y5 years | +24.3% | 0.0% | -10000.0% |
TOVX Selling, General & Administrative Expenses Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
---|---|---|---|---|---|---|---|
3 y | 3-year | -27.8% | +10.0% | -45.8% | +985.9% | -20.5% | at low |
5 y | 5-year | -27.8% | +55.5% | -45.8% | +985.9% | -39.0% | at low |
alltime | all time | -29.8% | +2392.1% | -49.3% | +675.5% | <-9999.0% | at low |
Theriva Biologics Selling, General & Administrative Expenses History
Date | Annual | Quarterly | TTM |
---|---|---|---|
Sep 2024 | - | $2.30 M(+56.9%) | $7.72 M(+37.1%) |
Jun 2024 | - | $1.47 M(-24.1%) | $5.63 M(-17.8%) |
Mar 2024 | - | $1.93 M(-4.4%) | $6.85 M(-3.8%) |
Dec 2023 | $7.12 M(-27.8%) | $2.02 M(+853.3%) | $7.12 M(-23.8%) |
Sep 2023 | - | $212.00 K(-92.1%) | $9.35 M(-19.1%) |
Jun 2023 | - | $2.69 M(+22.1%) | $11.55 M(+11.0%) |
Mar 2023 | - | $2.20 M(-48.2%) | $10.40 M(+5.5%) |
Dec 2022 | $9.86 M(+52.3%) | $4.25 M(+75.7%) | $9.86 M(+21.7%) |
Sep 2022 | - | $2.42 M(+56.8%) | $8.10 M(+15.9%) |
Jun 2022 | - | $1.54 M(-6.9%) | $6.99 M(+4.1%) |
Mar 2022 | - | $1.66 M(-33.4%) | $6.71 M(+3.6%) |
Dec 2021 | $6.47 M(+28.7%) | - | - |
Dec 2021 | - | $2.49 M(+90.8%) | $6.47 M(+25.9%) |
Sep 2021 | - | $1.30 M(+3.0%) | $5.14 M(+2.1%) |
Jun 2021 | - | $1.26 M(-10.9%) | $5.03 M(-0.4%) |
Mar 2021 | - | $1.42 M(+23.1%) | $5.05 M(+0.5%) |
Dec 2020 | $5.03 M(+9.8%) | $1.15 M(-3.7%) | $5.03 M(-2.5%) |
Sep 2020 | - | $1.20 M(-6.9%) | $5.16 M(+2.0%) |
Jun 2020 | - | $1.29 M(-7.7%) | $5.06 M(+5.0%) |
Mar 2020 | - | $1.39 M(+8.6%) | $4.82 M(+5.2%) |
Dec 2019 | $4.58 M(-20.0%) | $1.28 M(+16.8%) | $4.58 M(+1.8%) |
Sep 2019 | - | $1.10 M(+5.2%) | $4.50 M(-7.7%) |
Jun 2019 | - | $1.04 M(-9.5%) | $4.87 M(-7.4%) |
Mar 2019 | - | $1.15 M(-4.0%) | $5.26 M(-8.1%) |
Dec 2018 | $5.73 M(-23.3%) | $1.20 M(-18.5%) | $5.73 M(-12.6%) |
Sep 2018 | - | $1.47 M(+3.0%) | $6.55 M(-3.4%) |
Jun 2018 | - | $1.43 M(-11.7%) | $6.78 M(-3.0%) |
Mar 2018 | - | $1.62 M(-20.1%) | $7.00 M(-6.3%) |
Dec 2017 | $7.47 M(-26.4%) | $2.03 M(+18.9%) | $7.47 M(-16.2%) |
Sep 2017 | - | $1.71 M(+3.7%) | $8.91 M(-4.2%) |
Jun 2017 | - | $1.64 M(-21.3%) | $9.30 M(-5.1%) |
Mar 2017 | - | $2.09 M(-39.9%) | $9.81 M(-3.3%) |
Dec 2016 | $10.14 M(+25.6%) | $3.48 M(+65.9%) | $10.14 M(+10.2%) |
Sep 2016 | - | $2.10 M(-2.4%) | $9.20 M(+5.6%) |
Jun 2016 | - | $2.15 M(-11.5%) | $8.71 M(-0.9%) |
Mar 2016 | - | $2.43 M(-4.3%) | $8.79 M(+8.8%) |
Dec 2015 | $8.07 M(+34.3%) | $2.54 M(+58.0%) | $8.07 M(+9.1%) |
Sep 2015 | - | $1.60 M(-27.8%) | $7.40 M(+5.5%) |
Jun 2015 | - | $2.22 M(+29.7%) | $7.01 M(+6.2%) |
Mar 2015 | - | $1.71 M(-7.9%) | $6.60 M(+9.8%) |
Dec 2014 | $6.01 M(+3.1%) | $1.86 M(+52.6%) | $6.01 M(+5.2%) |
Sep 2014 | - | $1.22 M(-32.9%) | $5.72 M(-10.5%) |
Jun 2014 | - | $1.81 M(+61.7%) | $6.39 M(+9.5%) |
Mar 2014 | - | $1.12 M(-28.2%) | $5.83 M(0.0%) |
Dec 2013 | $5.83 M(+16.4%) | $1.56 M(-17.4%) | $5.83 M(+4.8%) |
Sep 2013 | - | $1.89 M(+50.2%) | $5.57 M(+17.2%) |
Jun 2013 | - | $1.26 M(+12.1%) | $4.75 M(+1.8%) |
Mar 2013 | - | $1.12 M(-13.4%) | $4.67 M(-6.9%) |
Dec 2012 | $5.01 M(+93.7%) | $1.29 M(+20.7%) | $5.01 M(+26.4%) |
Sep 2012 | - | $1.07 M(-8.8%) | $3.97 M(+14.1%) |
Jun 2012 | - | $1.18 M(-19.9%) | $3.48 M(+23.1%) |
Mar 2012 | - | $1.47 M(+489.6%) | $2.82 M(+9.1%) |
Dec 2011 | $2.59 M(+22.2%) | $249.00 K(-57.2%) | $2.59 M(+5.4%) |
Sep 2011 | - | $582.00 K(+11.1%) | $2.46 M(-0.8%) |
Jun 2011 | - | $524.00 K(-57.5%) | $2.48 M(-5.3%) |
Mar 2011 | - | $1.23 M(+956.6%) | $2.61 M(+23.1%) |
Dec 2010 | $2.12 M | $116.70 K(-80.6%) | $2.12 M(-34.9%) |
Date | Annual | Quarterly | TTM |
---|---|---|---|
Sep 2010 | - | $601.80 K(-9.2%) | $3.26 M(+8.3%) |
Jun 2010 | - | $662.60 K(-10.7%) | $3.01 M(+6.7%) |
Mar 2010 | - | $742.00 K(-40.9%) | $2.82 M(+5.6%) |
Dec 2009 | $2.71 M(+1.2%) | $1.26 M(+257.3%) | $2.68 M(+44.5%) |
Sep 2009 | - | $351.60 K(-25.8%) | $1.85 M(-12.1%) |
Jun 2009 | - | $474.00 K(-20.1%) | $2.11 M(-7.0%) |
Mar 2009 | - | $593.40 K(+37.1%) | $2.27 M(-15.3%) |
Dec 2008 | $2.68 M(-29.8%) | $432.80 K(-28.7%) | $2.68 M(-16.4%) |
Sep 2008 | - | $606.70 K(-4.2%) | $3.20 M(+0.2%) |
Jun 2008 | - | $633.60 K(-36.8%) | $3.19 M(-3.5%) |
Mar 2008 | - | $1.00 M(+4.6%) | $3.31 M(-13.2%) |
Dec 2007 | $3.81 M(+164.8%) | $958.50 K(+59.9%) | $3.81 M(+6.5%) |
Sep 2007 | - | $599.40 K(-20.0%) | $3.58 M(+12.0%) |
Jun 2007 | - | $748.90 K(-50.2%) | $3.20 M(+15.9%) |
Mar 2007 | - | $1.50 M(+106.7%) | $2.76 M(+91.7%) |
Dec 2006 | $1.44 M(+403.7%) | $727.50 K(+236.6%) | $1.44 M(+102.2%) |
Sep 2006 | - | $216.10 K(-30.6%) | $711.50 K(+43.6%) |
Jun 2006 | - | $311.20 K(+68.9%) | $495.40 K(+168.9%) |
Mar 2006 | - | $184.20 K(-53.8%) | $184.20 K(-93.7%) |
Dec 2005 | $285.70 K(-93.6%) | - | - |
Mar 2003 | - | $398.80 K(-19.1%) | $2.94 M(-34.4%) |
Dec 2002 | $4.48 M(-1.5%) | $493.00 K(-18.9%) | $4.48 M(-20.4%) |
Sep 2002 | - | $607.80 K(-57.9%) | $5.63 M(-7.0%) |
Jun 2002 | - | $1.44 M(-25.6%) | $6.06 M(+5.6%) |
Mar 2002 | - | $1.94 M(+18.0%) | $5.73 M(-31.2%) |
Dec 2001 | $4.55 M(+61.6%) | $1.64 M(+59.2%) | $8.33 M(+9.6%) |
Sep 2001 | - | $1.03 M(-7.9%) | $7.60 M(+7.2%) |
Jun 2001 | - | $1.12 M(-75.3%) | $7.09 M(+6.4%) |
Mar 2001 | - | $4.54 M(+398.4%) | $6.66 M(+136.4%) |
Dec 2000 | $2.82 M(+23.7%) | $910.30 K(+74.7%) | $2.82 M(+9.0%) |
Sep 2000 | - | $521.10 K(-24.6%) | $2.58 M(+0.8%) |
Jun 2000 | - | $691.40 K(-0.5%) | $2.56 M(+3.7%) |
Mar 2000 | - | $694.70 K(+2.6%) | $2.47 M(+8.6%) |
Dec 1999 | $2.28 M(-24.1%) | $677.10 K(+35.4%) | $2.28 M(+8.4%) |
Sep 1999 | - | $500.00 K(-16.7%) | $2.10 M(-19.2%) |
Jun 1999 | - | $600.00 K(+20.1%) | $2.60 M(-10.3%) |
Mar 1999 | - | $499.70 K(-0.1%) | $2.90 M(-3.3%) |
Dec 1998 | $3.00 M(-34.8%) | $500.00 K(-50.0%) | $3.00 M(-25.0%) |
Sep 1998 | - | $1.00 M(+11.1%) | $4.00 M(-7.0%) |
Jun 1998 | - | $900.00 K(+50.0%) | $4.30 M(-2.3%) |
Mar 1998 | - | $600.00 K(-60.0%) | $4.40 M(-4.3%) |
Dec 1997 | $4.60 M(-40.3%) | $1.50 M(+15.4%) | $4.60 M(-13.2%) |
Sep 1997 | - | $1.30 M(+30.0%) | $5.30 M(-13.1%) |
Jun 1997 | - | $1.00 M(+25.0%) | $6.10 M(+3.4%) |
Mar 1997 | - | $800.00 K(-63.6%) | $5.90 M(+7.3%) |
Dec 1996 | $7.70 M(+156.7%) | $2.20 M(+4.8%) | $5.50 M(+89.7%) |
Sep 1996 | - | $2.10 M(+162.5%) | $2.90 M(+81.3%) |
Jun 1996 | - | $800.00 K(+100.0%) | $1.60 M(+100.0%) |
Mar 1996 | - | $400.00 K(-200.0%) | $800.00 K(+100.0%) |
Dec 1995 | $3.00 M(-53.1%) | -$400.00 K(-150.0%) | $400.00 K(-50.0%) |
Sep 1995 | - | $800.00 K(+166.7%) | $800.00 K(-76.5%) |
Dec 1994 | $6.40 M(+77.8%) | - | - |
Mar 1994 | - | $300.00 K(-72.7%) | $3.40 M(-2.9%) |
Dec 1993 | $3.60 M | $1.10 M(-26.7%) | $3.50 M(+45.8%) |
Sep 1993 | - | $1.50 M(+200.0%) | $2.40 M(+166.7%) |
Jun 1993 | - | $500.00 K(+25.0%) | $900.00 K(+125.0%) |
Mar 1993 | - | $400.00 K | $400.00 K |
FAQ
- What is Theriva Biologics annual SGA?
- What is the all time high annual SGA for Theriva Biologics?
- What is Theriva Biologics annual SGA year-on-year change?
- What is Theriva Biologics quarterly SGA?
- What is the all time high quarterly SGA for Theriva Biologics?
- What is Theriva Biologics quarterly SGA year-on-year change?
- What is Theriva Biologics TTM SGA?
- What is the all time high TTM SGA for Theriva Biologics?
- What is Theriva Biologics TTM SGA year-on-year change?
What is Theriva Biologics annual SGA?
The current annual SGA of TOVX is $7.12 M
What is the all time high annual SGA for Theriva Biologics?
Theriva Biologics all-time high annual SGA is $10.14 M
What is Theriva Biologics annual SGA year-on-year change?
Over the past year, TOVX annual SGA has changed by -$2.74 M (-27.77%)
What is Theriva Biologics quarterly SGA?
The current quarterly SGA of TOVX is $2.30 M
What is the all time high quarterly SGA for Theriva Biologics?
Theriva Biologics all-time high quarterly SGA is $4.54 M
What is Theriva Biologics quarterly SGA year-on-year change?
Over the past year, TOVX quarterly SGA has changed by $0.00 (0.00%)
What is Theriva Biologics TTM SGA?
The current TTM SGA of TOVX is -$1.28 B
What is the all time high TTM SGA for Theriva Biologics?
Theriva Biologics all-time high TTM SGA is -$20.50 K
What is Theriva Biologics TTM SGA year-on-year change?
Over the past year, TOVX TTM SGA has changed by -$1.28 B (-16636.64%)